Harvard Business Review

AUGUST 17, 2012

Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. In the US, Cipla sells its products generic pharmaceutical companies such as Teva and Eagle. It has also formed a partnership with the Clinton Foundation to distribute ARVs in Africa. laç Ticaret Anonim

Company 11

Company Pharmaceuticals Business Model Fixed Costs 11

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. See The Risks of Prescription Drugs (Columbia 2010).

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JANUARY 26, 2011

billion RMB for an exchange traded fund (ETF) based on sustainability criteria which began trading on the SSE in August 2010. Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Strategy Driven

JANUARY 24, 2011

What did 2010 look like for you and your company? OnPoint Consulting’s 2010 Execution Gap Maker Round-Up… Execution Gap Maker #1: BP (Need I say more?) Execution Gap Maker #2: Nokia Nokia’s share of the worldwide market for mobile phones continued to slip in 2010. Did you struggle to regain your post-recession footing?

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

MARCH 1, 2011

And that's true in many areas: New devices, pharmaceuticals, and surgical techniques regularly get developed and incorporated into practice. Think instead about other industries. Convenience and coordination are the standards for most industries - but medicine falls far short.

Health Care 15

Health Care Biotechnology Mayo Pharmaceuticals 15

Harvard Business Review

OCTOBER 26, 2011

Between 2008 and 2010, over 25 US-based, cleantech-focused venture capital and private equity funds raised over $300 million in committed capital each, amounting to over $35 billion of capital committed for clean energy startups (here's an example ). Their behavior displays promising parallels to the early days of the biotechnology industry.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

JANUARY 31, 2013

According to recent McKinsey research (see " The $30 Trillion Decathlon "), consumption by developing economies could rise from $12 trillion annually in 2010 to $30 trillion in 2025, by which time these markets could account for nearly 70% of global demand for manufactured goods.

Globalization 9

Globalization Supply Chain Pharmaceuticals McKinsey 9

Harvard Business Review

FEBRUARY 24, 2015

A 2010 meta-analysis detailed many of the different issues that make divestiture so hard to evaluate consistently. The diverging fortunes of two recent spin-offs in the energy industry illustrate how financial markets value autonomy from the parent. and the competitive intensity of its industry.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

MARCH 6, 2015

Similarly, more than 40% of the 2010 Fortune 500 companies were founded by foreign-born immigrants or first-generation Americans, according to a study by The Partnership for a New American Economy. On the flip side, businesses lacking an international perspective among their leaders are often timid about moving into new markets.

Company 8

Company Globalization Software Wireless 8

Harvard Business Review

SEPTEMBER 11, 2014

We tested the approach with a company in the pharma industry. Our goal was to explore how the pharmaceutical firm’s customer lifetime value (CLV), customer retention, and sales were affected by the physicians’ experience of the drug coupled with their attitude regarding the salespeoples’ credibility and knowledge.

CRM 8

CRM Pharmaceuticals Survey Benchmarking 8

Harvard Business Review

SEPTEMBER 5, 2013

When we interviewed 45 such people across 39 companies in 8 industries in the United States and Europe, we found that by identifying low-value tasks to either drop completely, delegate to someone else or outsource, the average worker gained back roughly one day a week they could use for more important tasks.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

NOVEMBER 2, 2018

As a percent of workers’ compensation, employers’ health care spending has held steady at between 8% and 9% since 2010. This is the tactic that most industrialized countries use to keep health care affordable for their populations. Their premiums have been increasing 3% to 5% annually, rather modest by historic standards.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

MARCH 6, 2014

Just how big a problem this is for industry — and for one industry in particular — is illustrated by a recent study, which, ironically, claimed to uncover the kind of bias we don’t want to see when it comes to assessing the validity of data. But only if the PLoS study is itself true.

Peer Review 8

Peer Review Review Industry Wilde 8

Harvard Business Review

SEPTEMBER 20, 2011

There was little in the way of new industries, companies, jobs, profits, or taxes. A little-recognized NSF report released in September 2010, the 2008 Business R&D and Innovation Survey (BRDIS) , said that only 9% of public and private companies engaged in either product or service innovation between 2006 and 2008. It never happened.

Innovation 13

Innovation Supply Chain Offshoring Policies 13

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. This strategy will tap potential growth in emerging markets, limit the risks of misconduct, and improve public trust in the industry. The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1%

Reputation 8

Reputation Pharmaceuticals Price Business Model 8

Harvard Business Review

FEBRUARY 24, 2017

We analyzed required public disclosure information about congresspeople’s stock holdings as compiled by the Center for Responsive Politics , a nonpartisan nonprofit, in combination with a sample of S&P 500 performance data from 2005 to 2010. Not only did his wife invest between $610,000 and $1.5 We think the answer is a clear yes.

Conflict of Interest 8

Conflict of Interest Committee Collins Politics 8

Harvard Business Review

JANUARY 4, 2017

There are similar stories in the electronics industry, pet food, pharmaceuticals, and even national security. Industry groups such as EICC, GeSI, and AIAG have made substantial progress in identifying conflict-free smelters in the region, which enables their suppliers to shift to these smelters. We wanted to find out.

Supply Chain 9

Supply Chain Productivity Products Company 9